Adapting Preclinical Benchmarks for First-in-Human Trials of Human Embryonic Stem Cell-Based Therapies

Area of Science:

• Stem Cell Biology
• Translational Medicine
• Regulatory Science

Background:

• Human embryonic stem cell (hESC)-based therapies are advancing towards clinical application.
• Existing preclinical regulatory frameworks require adaptation for stem cell translational medicine.
• Ethical considerations for first-in-human (FIH) trials are paramount.

Purpose of the Study:

• To assess the ethical justification for advancing hESC-based therapies from preclinical studies to FIH trials.
• To examine and apply existing regulatory frameworks for preclinical requirements to hESC interventions.
• To ensure robust protection for research participants in early-phase clinical trials.

Main Methods:

• Review of existing regulatory frameworks for preclinical requirements.
• Assessment of framework applicability to hESC-based interventions.
• Analysis of specific preclinical benchmarks (identity, purity, potency, viability) in the context of hESC heterogeneity.

Main Results:

• Dynamic heterogeneity of hESC products necessitates rethinking identity and purity benchmarks.
• Potency and viability benchmarks require further specification for hESC-based products.
• Adaptation of preclinical requirements is crucial for managing safety risks and predicting in vivo effects.

Conclusions:

• Preclinical benchmarks for hESC therapies need adaptation to account for product heterogeneity.
• Mutual learning between researchers and regulators is essential for ethical and safe clinical translation.
• Revised application of preclinical standards will support the transition of hESC research to clinical practice.